183 results on '"Holth, Arild"'
Search Results
2. Lymphovascular invasion and p16 expression are independent prognostic factors in stage I vulvar squamous cell carcinoma
3. Molecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations
4. Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance
5. Different Frequency and Clinical Role for MTAP Loss in Pleural and Peritoneal Mesothelioma
6. Correction to: Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma
7. Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma
8. Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma
9. Stathmin is an Independent Prognostic Marker of Poor Outcome in Uterine Leiomyosarcoma
10. Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance
11. Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma
12. Expression of the cancer stem cell marker SSEA1 is associated with poor survival in metastatic high-grade serous carcinoma
13. SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma
14. Lymphovascular invasion and p16 expression are independent prognostic factors in stage I vulvar squamous cell carcinoma
15. Expression, activation and clinical relevance of CHK1 and CHK2 in metastatic high-grade serous carcinoma
16. Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma
17. Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing
18. The diagnostic role of PTEN and ARID1A in serous effusions
19. MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma
20. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival
21. Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma
22. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions
23. Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma
24. TGFβ splicing and canonical pathway activation in high-grade serous carcinoma
25. Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions
26. VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival
27. Gene expression signatures of primary and metastatic uterine leiomyosarcoma
28. Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance
29. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival
30. Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma
31. Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases
32. Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome
33. Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma
34. AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma
35. HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases
36. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions
37. The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high‐grade serous carcinoma
38. Expression of palladin is associated with disease progression in metastatic high‐grade serous carcinoma
39. Chromosome Translocation t(14;21)(q11;q22) Activates Both OLIG1 and OLIG2 in Pediatric T-cell Lymphoblastic Malignancies and May Signify Adverse Prognosis
40. The Chemokine Receptor CXCR4 is More Frequently Expressed in Breast Compared to Other Metastatic Adenocarcinomas in Effusions
41. Flow Cytometric Immunophenotyping of Cancer Cells in Effusion Specimens:: Diagnostic and Research Applications
42. Fusion of the COL1A1 and FYN Genes in Epithelioid Osteoblastoma
43. The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high‐grade serous carcinoma.
44. Chromosome Translocation t(14;21)(q11;q22) Activates Both OLIG1 and OLIG2 in Pediatric T-cell Lymphoblastic Malignancies and May Signify Adverse Prognosis.
45. Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma
46. Expression of 14-3-3 sigma and eta proteins is unrelated to survival in metastatic high-grade serous carcinoma
47. The diagnostic role of PTEN and ARID1A in serous effusions
48. L1CAM as a prognostic marker in stage I endometrial cancer: a validation study
49. CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma
50. Abstract 401: Gene expression signatures differentiate primary and metastatic uterine leiomyosarcoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.